Prescient is an evidence-based decision-support partner to the pharmaceutical and biotech industries whose mission is to optimally shape new product, brand and mature product planning strategies.

Our diverse yet integrated skillsets and methodologies ensure our clients’ key decisions are objectively assessed from both a clinical and commercial perspective, resulting in differentiated products and offerings.

 

Shaping Decisions Driving Value

Our People

Prescient’s team consists of highly experienced executives who share our core values of thinking collaboratively, creatively and constructively. We effectively integrate different skills and perspectives into a single client-engagement team.

Our Approach

The format and scope of our engagements are customized to meet our clients’ needs and our ‘best-in-front’ team philosophy ensures access to the necessary levels of expertise and thinking.

Our Clients

We engage directly with a number of functions supporting new product, brand and mature product planning activities; to view a full list of these, please click the
link below.

Latest News

Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCam …

Discovery of a novel Wnt inhibitor with potential to eradicate colorectal cancer stem cells

Breast milk sugar may protect babies against deadly infection

Finding new targets to treat vascular damage

Global superbug response needs $5bn each year, experts predict

Pfizer to acquire small molecule anti-infective business from AstraZeneca

Clinical Forum for Operational Excellence 2016

Study examines reasons for high cost of prescriptions drugs in US

Soluble corn fiber can help young women build bone, and older women preserve bone

AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment f …

Bayer and CRISPR Therapeutics joint venture, named Casebia Therapeutics, establishes operations in C …

Diabetes drug may also offer vascular protection

Natural compound from a deep-water marine sponge found to reduce pancreatic tumor size

Esketamine receives Breakthrough Therapy Designation from FDA for major depressive disorder with imm …

Researchers develop safer opioid painkiller from scratch

Leap reverse merges, secures $30M for I/O antibodies

Cancer upstart CBT closes $9.7M Series A; OrbiMed lead investor

EXCLUSIVE: Stealthy Arcus emerges with $120M to make personalized I/O therapy a reality

Struggling CTI reveals new pacritinib data, misses a primary endpoint

Ferring buys rights to PhIII pain drug from Seikagaku

CardioCell stem cells ‘improve well-being’ of heart failure patients

TG wraps up orphan tags for both its clinical candidates

Perpetual life sciences investor Sofinnova raises nearly $600M

Chutes & Ladders: Medivation VP moves on to BeiGene after Pfizer buy

Fresh from AbbVie deal, argenx sees revenue growth but cuts two R&D collabs

GenVec, encamped in penny-stock territory, risks Nasdaq delisting

Adocia scraps diabetic foot ulcer program following PhIII flop

Novartis touts positive data from PhIII multiple sclerosis trial

Denali grabs $130M more as it heads into the clinic, reveals deals

BioLineRx sets up Chinese JV, continuing trend for Sino-Israeli alliances

Amidst price criticism, Mylan to debut first generic of EpiPen in USA

Leap Therapeutics to acquire Macrocure

Sanofi and Regeneron present positive new data on Praluent at ESC

New Repatha analyses show efficacy and safety across risk groups

Stada Arz board shakeup as chairman ousted

Greece: Course of payments from the Organization to the healthcare providers

PhRMA Fact Check: The truth about biopharmaceutical patents

Look back at pharma news to August 26

Daiichi and UCB file for new indication for lacosamide in Japan

Vanda Pharma leaps as court rules Fanapt patent valid

Russian watchdog investigating cartel in Russian pharma market

Global drugmakers to conduct clinical trials in Ukraine

Denali deals reflect confidence in neurodegenerative disease space

Eisai gets new indication for Treakisym in Japan

New indication approved for Chugai’s Xeloda in Japan

Medical News Today: How sitting in traffic jams can harm your health

Medical News Today: Should I Worry About a Cherry Angioma? Get the Facts

Medical News Today: Replacing old memories with new for people who fear spiders

Medical News Today: All You Need to Know About Nephritis

Medical News Today: Understanding the unhappy side of serotonin

Medical News Today: Baby simulator programs 'increase teen pregnancy risk, not reduce it'

Medical News Today: Coffee intake depends on gene variation, study suggests

Medical News Today: Peritonitis: Causes, Symptoms, and Treatment

Medical News Today: Soluble corn fiber may improve women's bone health

Medical News Today: Marijuana use leads to laziness, study suggests

Medical News Today: Reducing prescription opioid addiction by switching receptors

Medical News Today: Diabetes-related vision loss growing worldwide

Medical News Today: Bacterial Pneumonia: Get the Facts

Medical News Today: Mycoplasma Pneumoniae: What You Need to Know

Medical News Today: Fracking chemicals may pose threat to fertility

NICE backs non-surgical option for fibroids

Stafford hospital shuts A&E to children

Novartis’ MS drug hits primary PhIII target

NHS deficit narrows in first quarter

FDA rejects Amgen’s Parsabiv

GPs report drug shortages

Servier’s Lonsurf backed for NHS use

Cell Medica links with UCL in research deal

NICE expands NHS treatment options for CML, lung cancer

AbbVie’s venetoclax joins UK’s early access scheme

NICE widens scope of Bayer’s Eylea

AZ sells antibiotics to Pfizer

Clovis’ ovarian cancer drug gets US priority review

DS Biopharma spins out Afimmune

EU clear’s Gilead’s Truvada for HIV PrEP

More News